Justin Eyquem
@j-eyquem.bsky.social
Eyquem Lab _ Genome editing and Synthetic Immunologist at UCSF.
Investigator @Gladstone Institutes and Parker Institute for Cancer Immunotherapy
Investigator @Gladstone Institutes and Parker Institute for Cancer Immunotherapy
Reposted by Justin Eyquem
Azalea grew out of collaborative research conducted at the Innovative Genomics Institute in Jennifer Doudna’s lab and in Justin Eyquem’s lab as part of the Gladstone-UCSF Institute of Genomic Immunology.
@j-eyquem.bsky.social
@innovativegenomics.bsky.social
@j-eyquem.bsky.social
@innovativegenomics.bsky.social
Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient
Azalea Therapeutics launches with $82M to advance precision in vivo genome engineering, creating therapeutic cells directly inside patients....
www.globenewswire.com
November 14, 2025 at 9:10 PM
Azalea grew out of collaborative research conducted at the Innovative Genomics Institute in Jennifer Doudna’s lab and in Justin Eyquem’s lab as part of the Gladstone-UCSF Institute of Genomic Immunology.
@j-eyquem.bsky.social
@innovativegenomics.bsky.social
@j-eyquem.bsky.social
@innovativegenomics.bsky.social
Genomic medicine has transformed lives through ex vivo cell therapies, now it’s time to make it scalable.
Today we unveil Azalea Therapeutics, making in vivo genomic medicine a reality without compromising precision or specificity, starting with T cells!
Today we unveil Azalea Therapeutics, making in vivo genomic medicine a reality without compromising precision or specificity, starting with T cells!
Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Their goal? The ultimate CRISPR-based in vivo CAR-T. @endpts.com - endpoints.news/jennifer-dou...
Jennifer Doudna startup launches with $82M to apply new CRISPR delivery technology to in vivo CAR-T
Nobel laureate Jennifer Doudna's Azalea Therapeutics raises $82M to develop new CRISPR delivery system for in vivo CAR-T cell therapies targeting blood cancers.
endpoints.news
November 4, 2025 at 5:58 PM
Genomic medicine has transformed lives through ex vivo cell therapies, now it’s time to make it scalable.
Today we unveil Azalea Therapeutics, making in vivo genomic medicine a reality without compromising precision or specificity, starting with T cells!
Today we unveil Azalea Therapeutics, making in vivo genomic medicine a reality without compromising precision or specificity, starting with T cells!
Exciting collaboration combining multiplex epigenetic reprogramming and site-specific payload integration!
Integrated epigenetic and genetic programming of primary human T cells - @gladstoneinst.bsky.social @ucsanfrancisco.bsky.social @j-eyquem.bsky.social @marsonlab.bsky.social go.nature.com/3WOJJAJ
Integrated epigenetic and genetic programming of primary human T cells - Nature Biotechnology
Multiplexed editing in primary human T cells generates enhanced immune cell therapies.
go.nature.com
October 21, 2025 at 5:59 PM
Exciting collaboration combining multiplex epigenetic reprogramming and site-specific payload integration!
The Weill Cancer Hub is fostering groundbreaking @ucsanfrancisco.bsky.social - @stanford-cancer.bsky.social collaborations to develop transformative cancer therapies. I’m grateful to co-lead one of the selected teams with @mfgrp.bsky.social to advance next-generation in vivo CAR T cell therapy!
Backed by a $100M gift from Joan and Sandy Weill, UCSF and @stanfordmedicine.bsky.social @stanford-cancer.bsky.social are launching Weill Cancer Hub West, a $200M initiative in team science to accelerate cancer research and improve care over the next decade.
tiny.ucsf.edu/rZIspe
tiny.ucsf.edu/rZIspe
Gift Launches $200M Initiative for the Weill Cancer Hub West
A $100 million matching grant from the Weill Family Foundation is bringing together two leading cancer centers to launch the Weill Cancer Hub West — an innovative collaboration among some of the natio...
www.ucsf.edu
July 25, 2025 at 6:07 AM
The Weill Cancer Hub is fostering groundbreaking @ucsanfrancisco.bsky.social - @stanford-cancer.bsky.social collaborations to develop transformative cancer therapies. I’m grateful to co-lead one of the selected teams with @mfgrp.bsky.social to advance next-generation in vivo CAR T cell therapy!
Reposted by Justin Eyquem
Backed by a $100M gift from Joan and Sandy Weill, UCSF and @stanfordmedicine.bsky.social @stanford-cancer.bsky.social are launching Weill Cancer Hub West, a $200M initiative in team science to accelerate cancer research and improve care over the next decade.
tiny.ucsf.edu/rZIspe
tiny.ucsf.edu/rZIspe
Gift Launches $200M Initiative for the Weill Cancer Hub West
A $100 million matching grant from the Weill Family Foundation is bringing together two leading cancer centers to launch the Weill Cancer Hub West — an innovative collaboration among some of the natio...
www.ucsf.edu
July 23, 2025 at 3:40 PM
Backed by a $100M gift from Joan and Sandy Weill, UCSF and @stanfordmedicine.bsky.social @stanford-cancer.bsky.social are launching Weill Cancer Hub West, a $200M initiative in team science to accelerate cancer research and improve care over the next decade.
tiny.ucsf.edu/rZIspe
tiny.ucsf.edu/rZIspe
Excited to share our latest work, now out in
@NatureBiotech
! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇
www.nature.com/articles/s41...
@NatureBiotech
! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇
www.nature.com/articles/s41...
SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci - Nature Biotechnology
Primary T cells with multiple genetic modifications are rapidly isolated by negative selection.
www.nature.com
February 5, 2025 at 7:03 PM
Excited to share our latest work, now out in
@NatureBiotech
! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇
www.nature.com/articles/s41...
@NatureBiotech
! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇
www.nature.com/articles/s41...
🚨New paper alert! 🚨 Our latest work in
@cp-immunity.bsky.social shows that Ark313, an evolved AAV variant enables in vivo genetic engineering of murine T cells! 🧵👇
sciencedirect.com/science/arti...
@cp-immunity.bsky.social shows that Ark313, an evolved AAV variant enables in vivo genetic engineering of murine T cells! 🧵👇
sciencedirect.com/science/arti...
In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313
Genetic engineering of T cells in mouse models is essential for investigating immune mechanisms. We aimed to develop an approach to manipulate T cells…
sciencedirect.com
February 4, 2025 at 8:50 PM
🚨New paper alert! 🚨 Our latest work in
@cp-immunity.bsky.social shows that Ark313, an evolved AAV variant enables in vivo genetic engineering of murine T cells! 🧵👇
sciencedirect.com/science/arti...
@cp-immunity.bsky.social shows that Ark313, an evolved AAV variant enables in vivo genetic engineering of murine T cells! 🧵👇
sciencedirect.com/science/arti...
Reposted by Justin Eyquem
Wonderful to see the #immunology community growing here.
The first starter pack is full (they cap at 150), so I created a second one. Let me know if you'd like to be added
go.bsky.app/PY5tCas
go.bsky.app/FmERUoD
The first starter pack is full (they cap at 150), so I created a second one. Let me know if you'd like to be added
go.bsky.app/PY5tCas
go.bsky.app/FmERUoD
November 15, 2024 at 12:35 PM
Wonderful to see the #immunology community growing here.
The first starter pack is full (they cap at 150), so I created a second one. Let me know if you'd like to be added
go.bsky.app/PY5tCas
go.bsky.app/FmERUoD
The first starter pack is full (they cap at 150), so I created a second one. Let me know if you'd like to be added
go.bsky.app/PY5tCas
go.bsky.app/FmERUoD